Harnessing AI in Healthcare: A Unique Opportunity for Diabetes Treatment in India

By Sumona Bose

January 11, 2024

The Rising Burden of Diabetes in India: A Unique Opportunity for AI

India’s escalating diabetes cases present a unique challenge, but also a unique opportunity. The vast amount of data available could be harnessed through electronic medical records, positioning India at the forefront of research in this area. The application of artificial intelligence (AI) and machine learning (ML) could provide valuable insights and help devise bespoke solutions.

Figure 1: Indian Map showing the distribution of Diabetes

 

AI and ML: A Game Changer in Chronic Disease Management

AI and ML are already making strides in chronic disease management, particularly diabetes. These technologies are being used to predict diabetes risk based on genomic data, diagnose diabetes using EHR data, and predict complications such as nephropathy and retinopathy. Google’s AI research unit, in collaboration with several Indian ophthalmology centres, has made significant advances in automated diagnosis and grading of diabetic retinopathy based on fundus photographs. The adoption of these technologies could dramatically increase the detection and early treatment of diabetic complications.

The Potential of AI and ML in India’s Healthcare System

The potential of AI and ML is particularly significant in India, where diabetes prevalence is estimated at 8-10%, with a slightly lower burden in rural areas compared to urban areas. However, the prevalence of diabetes in Delhi is estimated at around 27%, with 46% or more of the population having prediabetes. Such an early and extensive occurrence of diabetes could place a significant burden on the healthcare system.

AI and ML are only as good as the data used to generate this intelligence. India is sometimes referred to as a “country with no records”, highlighting the general lack of record-keeping as an essential part of medical practice. However, this burden of disease could be transformed into an opportunity if all data is harnessed in a usable form and AI and ML are used to generate insights and solutions specific to our population. A concerted and collective effort is needed by the government and large associations, like the Endocrine Society of India, to initiate data collections and research.

In conclusion, AI’s evolution in healthcare, particularly in the management of diabetes, offers a unique opportunity for India. With the right strategies and collaborations, AI could significantly improve the country’s healthcare system and contribute to better patient outcomes.

Reference url

Recent Posts

Joint Scientific Consultation EU
Joint Scientific Consultation EU Strategies for Medical Device Companies

By João L. Carapinha

June 19, 2026

The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...
EU Joint Clinical Assessment
Insights on EU Joint Clinical Assessment for High-Risk Medical Devices

By João L. Carapinha

June 19, 2026

EU Joint Clinical Assessment is a distinct, harmonised process that operates separately from CE marking. It produces comparative clinical evidence on selected high-risk devices to support more consistent national reimbursement decisions across EU member states. Insights from the
LesionAttn Skin Cancer AI
LesionAttn Skin Cancer AI Enhances Fairness in Dermatological Diagnostics

By João L. Carapinha

June 19, 2026

LesionAttn Skin Cancer AI tackles a critical flaw in current skin cancer detection tools: models that unconsciously rely on background skin features differing between men and women, producing unequal accuracy across genders. By steering neural networks to focus on the actual lesion instead of the...